DK1732887T3 - 1-(1H-Indol-1-yl)-3-(4-mehtylpiperazin-1-yl)-1-phenylpropan-2-ol-derivater og beslægtede forbindelser som modulatorer af norepinefrin (NE)- og serotonin (5-HT)-aktivitet og monoamin-genoptagelse til behandling af vasomotoriske symptomer (VMS) - Google Patents

1-(1H-Indol-1-yl)-3-(4-mehtylpiperazin-1-yl)-1-phenylpropan-2-ol-derivater og beslægtede forbindelser som modulatorer af norepinefrin (NE)- og serotonin (5-HT)-aktivitet og monoamin-genoptagelse til behandling af vasomotoriske symptomer (VMS)

Info

Publication number
DK1732887T3
DK1732887T3 DK05730271T DK05730271T DK1732887T3 DK 1732887 T3 DK1732887 T3 DK 1732887T3 DK 05730271 T DK05730271 T DK 05730271T DK 05730271 T DK05730271 T DK 05730271T DK 1732887 T3 DK1732887 T3 DK 1732887T3
Authority
DK
Denmark
Prior art keywords
phenylpropan
vms
methylpiperazin
norepinephrine
indol
Prior art date
Application number
DK05730271T
Other languages
Danish (da)
English (en)
Inventor
Callain Younghee Kim
Paige Erin Mahaney
Eugene John Trybulski
Puwen Zhang
Eugene Anthony Terefenko
Casey Cameron Mccomas
Michael Anthony Marella
Richard Dale Coghlan
Gavin David Heffernan
Stephen Todd Cohn
An Thien Vu
Joseph Peter Sabatucci
Fei Ye
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of DK1732887T3 publication Critical patent/DK1732887T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/42—Benzopyrazines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK05730271T 2004-03-30 2005-03-29 1-(1H-Indol-1-yl)-3-(4-mehtylpiperazin-1-yl)-1-phenylpropan-2-ol-derivater og beslægtede forbindelser som modulatorer af norepinefrin (NE)- og serotonin (5-HT)-aktivitet og monoamin-genoptagelse til behandling af vasomotoriske symptomer (VMS) DK1732887T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55765104P 2004-03-30 2004-03-30
US56986304P 2004-05-11 2004-05-11
US11/091,885 US7517899B2 (en) 2004-03-30 2005-03-28 Phenylaminopropanol derivatives and methods of their use
PCT/US2005/010511 WO2005097744A1 (fr) 2004-03-30 2005-03-29 Derives de 1-(1h-indol-1-yl)-3-(4-methylpiperazine-1-yl)-1-phenyle propan-2-ol et composes associes utilises en tant que modulateurs de l'activite de la norepinephrine (ne) et de la serotonine (5-ht) et reabsorption de la monoamine dans le traitement des symptomes vasomoteurs

Publications (1)

Publication Number Publication Date
DK1732887T3 true DK1732887T3 (da) 2008-04-28

Family

ID=34964018

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05730271T DK1732887T3 (da) 2004-03-30 2005-03-29 1-(1H-Indol-1-yl)-3-(4-mehtylpiperazin-1-yl)-1-phenylpropan-2-ol-derivater og beslægtede forbindelser som modulatorer af norepinefrin (NE)- og serotonin (5-HT)-aktivitet og monoamin-genoptagelse til behandling af vasomotoriske symptomer (VMS)

Country Status (20)

Country Link
US (3) US7517899B2 (fr)
EP (1) EP1732887B1 (fr)
JP (1) JP2007531751A (fr)
KR (1) KR20060134186A (fr)
AR (1) AR048675A1 (fr)
AT (1) ATE383337T1 (fr)
AU (1) AU2005230900A1 (fr)
BR (1) BRPI0509390A (fr)
CA (1) CA2560967A1 (fr)
CR (1) CR8639A (fr)
DE (1) DE602005004268T2 (fr)
DK (1) DK1732887T3 (fr)
EC (1) ECSP066899A (fr)
ES (1) ES2299025T3 (fr)
IL (1) IL178185A0 (fr)
NO (1) NO20064892L (fr)
PE (1) PE20060288A1 (fr)
PL (1) PL1732887T3 (fr)
TW (1) TW200536532A (fr)
WO (1) WO2005097744A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7414052B2 (en) * 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
CA2569238A1 (fr) * 2004-06-01 2005-12-15 F. Hoffmann-La Roche Ag Inhibiteur du recaptage des monoamines
CA2603818A1 (fr) * 2005-04-29 2006-11-09 Wyeth Procede pour preparer des oxindoles 3,3-disubstitues et des thio-oxindoles
WO2007041257A2 (fr) * 2005-09-29 2007-04-12 Wyeth Derives de propylamine substituee et procedes d'utilisation associe
AU2006297414A1 (en) * 2005-09-29 2007-04-12 Wyeth 1- (1H- indol- 1-yl) -3- (methylamino) -1- phenylpropan-2-ol derivatives and related compounds as modulators of the monoamine reuptake for the treatment of vasomotor symptoms (VMS)
DE602006009138D1 (de) * 2005-11-30 2009-10-22 Hoffmann La Roche 3-amino-2-arylpropylazaindole und anwendungen davon
EP1960355A1 (fr) * 2005-11-30 2008-08-27 F.Hoffmann-La Roche Ag 3-amino-1-arylpropyl indoles et indoles a substitution azo
ES2368416T3 (es) 2005-11-30 2011-11-17 F. Hoffmann-La Roche Ag Procedimiento para la síntesis de 3-amino-1-arilpropil-indoles.
US20080146645A1 (en) * 2006-08-24 2008-06-19 Wyeth Process for Preparing Indolinone Phenylaminopropanol Derivatives
US7671238B2 (en) * 2006-10-04 2010-03-02 Wyeth Llc Arylamino-arylpropanolamine derivatives and methods of their use
HUP1000598A2 (en) 2010-11-05 2012-09-28 Richter Gedeon Nyrt Indole derivatives
CN103384661B (zh) * 2011-01-20 2016-08-10 默沙东公司 盐皮质激素受体拮抗剂
TWI574946B (zh) 2012-07-17 2017-03-21 葛蘭素史密斯克藍智慧財產權有限公司 化合物
KR101460738B1 (ko) * 2012-08-23 2014-11-12 한국과학기술연구원 신규한 2-나프틸 프로판-2-올 화합물, 이를 포함하는 약학 조성물, 및 상기 약학 조성물을 포함하는 제제
CN112423743A (zh) 2018-07-03 2021-02-26 伊利诺伊大学评议会 未折叠蛋白反应的激活剂
US20220296604A1 (en) * 2019-08-08 2022-09-22 New York University Indole compounds as modulators of rage activity and uses thereof
CN114539080A (zh) * 2022-03-02 2022-05-27 八叶草健康产业研究院(厦门)有限公司 一种2-(2-氨基-6-氯苯基)-乙酸钠的制备方法
WO2024158872A1 (fr) * 2023-01-25 2024-08-02 The Rockefeller University Inhibiteurs 1,3-indole-propanamides de la plpro/nsp3 du sars-cov-2 et leurs dérivés

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3454554A (en) 1960-10-14 1969-07-08 Colgate Palmolive Co Aminoalkyliminodibenzyl compounds
US4123543A (en) 1971-09-16 1978-10-31 Ab Kabi Derivatives of substituted indoline lactans with effect on the central nervous system
CS175831B1 (fr) 1974-12-17 1977-05-31
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4310524A (en) 1980-04-11 1982-01-12 Richardson-Merrell, Inc. TCA Composition and method for rapid onset antidepressant therapy
PH18686A (en) 1981-05-26 1985-08-29 Merck & Co Inc 1-(3 halo-2-pyridinyl) piperazine
US4535186A (en) 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
EP0135905A3 (fr) 1983-09-29 1986-10-22 ASTA Pharma Aktiengesellschaft (Alcoyl-hydroxy-phenyl)-1-hydroxy-1-(alcoylamino)-2-propanes
ZA864772B (en) 1985-07-02 1987-02-25 Merrell Dow Pharma Novel chemical compounds
ZA885824B (en) 1987-08-14 1989-04-26 Merrell Dow Pharma Novel antidepressants
US4826844A (en) 1987-09-30 1989-05-02 American Home Products Corporation Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols
AU652759B2 (en) 1990-06-01 1994-09-08 Aventisub Ii Inc. (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)- 4-piperidinemethanol
US5648511A (en) 1990-11-19 1997-07-15 G.D. Searle & Co. Method for making intermediates useful in the synthesis of retroviral protease inhibitors
FR2708605A1 (fr) 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2686878B1 (fr) 1992-01-30 1995-06-30 Sanofi Elf Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant.
US5502047A (en) 1993-03-22 1996-03-26 Kavey; Neil B. Treatment for insomnia
US5516774A (en) 1993-07-29 1996-05-14 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
FR2708606B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
FR2714378B1 (fr) 1993-12-24 1996-03-15 Sanofi Sa Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
AU3414295A (en) 1994-08-19 1996-03-14 Nps Pharmaceuticals, Inc. Methods and compounds active at metabotropic glutamate receptors useful for treatment of neurological disorders and diseases
AU5857296A (en) 1995-05-17 1996-11-29 Eli Lilly And Company Use of leukotriene antagonists for alzheimer's disease
FR2740136B1 (fr) 1995-10-24 1998-01-09 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant
GB9606016D0 (en) 1996-03-22 1996-05-22 Smithkline Beecham Plc Novel use
JP2000507945A (ja) 1996-03-25 2000-06-27 イーライ・リリー・アンド・カンパニー 痛みを処置する方法
WO1998014208A1 (fr) 1996-09-30 1998-04-09 President And Fellows Of Harvard College Ligands reactifs et complexes covalents de ligands et proteines
FR2757157B1 (fr) 1996-12-13 1999-12-31 Sanofi Sa Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant
IL138084A0 (en) 1998-03-02 2001-10-31 Lilly Co Eli Fluoxetine hydrochloride for decreasing hot flashes
TW528754B (en) 1998-04-29 2003-04-21 Wyeth Corp Indolyl derivatibes as serotonergic agents
CA2336962A1 (fr) 1998-07-13 2000-01-20 Alan Mueller Procedes et composes permettant de traiter la depression et d'autres troubles
ES2305606T3 (es) 1999-04-06 2008-11-01 Sepracor Inc. Succinato de o-desmetilvenlafaxina.
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
ATE305307T1 (de) 1999-07-01 2005-10-15 Pharmacia & Upjohn Co Llc Reboxetin zur behandlung von migränekopfschmerzen
FR2804115B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
FR2804114B1 (fr) 2000-01-25 2002-03-08 Sanofi Synthelabo Nouveaux derives de 1,3-dihydro-2h-indol-2-one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
AU2001249397A1 (en) 2000-03-24 2001-10-08 Cor Therapeutics, Inc. Oxindole inhibitors of factor xa
US20030008860A1 (en) 2002-05-09 2003-01-09 Bakker-Arkema Rebecca Guggemos Treatment of congestive heart failure
GB2362826A (en) 2000-06-02 2001-12-05 Lilly Co Eli A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
CA2422055A1 (fr) 2000-09-11 2002-03-21 Sepracor, Inc. Ligands pour les recepteurs de monoamine et transporteurs, et procedes d'utilisation de ces derniers
EP1360169B2 (fr) 2001-02-12 2017-05-24 Wyeth LLC Sel de succinate de o-desmethyl-venlafaxine
JP2004525940A (ja) 2001-03-29 2004-08-26 イーライ・リリー・アンド・カンパニー 火照りの処置のためのデュロキセチン
EP1266659A1 (fr) 2001-06-11 2002-12-18 Pantarhei Bioscience B.V. Pyridoxal en combination avec inhibiteur de reprise de sérotonine pour le traitement des éclats
AR035083A1 (es) 2001-07-25 2004-04-14 Wyeth Corp Derivados azaheterociclilmetilicos de 7,8-dihidro-6h-5-oxa-1-aza-fenantreno, composiciones farmaceuticas, el uso de dichos derivados para la preparacion de un medicamento antidepresivo e intermediarios
WO2004089942A2 (fr) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Derives de benzimidazolidinone utilises en tant qu'agents muscariniques
US20040259850A1 (en) 2001-10-31 2004-12-23 Alves Stephen E. Method for treating or preventing symptoms of hormonal variation including hot flashes
US6602911B2 (en) 2001-11-05 2003-08-05 Cypress Bioscience, Inc. Methods of treating fibromyalgia
CA2479350A1 (fr) 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Inhibiteurs de recaptage de 5-ht pour le traitement de syndromes de la douleur viscerale
TW200402289A (en) 2002-05-17 2004-02-16 Wyeth Corp Methods of treating gastrointestinary and genitourinary pain disorders
US20040092519A1 (en) 2002-08-14 2004-05-13 Fred Hassan New treatment for hot flashes
US7345096B2 (en) 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US20040180879A1 (en) 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US20040152710A1 (en) 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7531543B2 (en) * 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US7491723B2 (en) * 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US20050130987A1 (en) 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7419980B2 (en) * 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7524846B2 (en) * 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7365076B2 (en) * 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US20050165082A1 (en) * 2003-12-16 2005-07-28 Wyeth Methods of treating vasomotor symptoms
US7414052B2 (en) * 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use

Also Published As

Publication number Publication date
US20090093469A1 (en) 2009-04-09
US20090099164A1 (en) 2009-04-16
WO2005097744A1 (fr) 2005-10-20
JP2007531751A (ja) 2007-11-08
PL1732887T3 (pl) 2008-05-30
US20050222148A1 (en) 2005-10-06
DE602005004268D1 (de) 2008-02-21
AU2005230900A1 (en) 2005-10-20
EP1732887B1 (fr) 2008-01-09
DE602005004268T2 (de) 2009-01-02
NO20064892L (no) 2006-12-13
IL178185A0 (en) 2006-12-31
AR048675A1 (es) 2006-05-17
EP1732887A1 (fr) 2006-12-20
BRPI0509390A (pt) 2007-09-18
ECSP066899A (es) 2006-11-24
TW200536532A (en) 2005-11-16
PE20060288A1 (es) 2006-05-23
US7517899B2 (en) 2009-04-14
CA2560967A1 (fr) 2005-10-20
KR20060134186A (ko) 2006-12-27
CR8639A (es) 2007-06-08
ES2299025T3 (es) 2008-05-16
ATE383337T1 (de) 2008-01-15

Similar Documents

Publication Publication Date Title
DK1732887T3 (da) 1-(1H-Indol-1-yl)-3-(4-mehtylpiperazin-1-yl)-1-phenylpropan-2-ol-derivater og beslægtede forbindelser som modulatorer af norepinefrin (NE)- og serotonin (5-HT)-aktivitet og monoamin-genoptagelse til behandling af vasomotoriske symptomer (VMS)
NO20083057L (no) Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer
NO20075693L (no) Modulerende forbindelser av indolamin-2,3-dioksygenase og fremgangsmater for anvendelse av samme
NO20081975L (no) Diarylamin-inneholdende forbindelser og sammensetninger, og deres anvendelse som modulatorer av C-kit-reseptorer
DK1558582T3 (da) Diaryl og arylheteroarylureaderivater som modulatorer af aktiviteten af 5-HT2A-serotoninreceptoren anvendelige til profylakse eller behandling af forstyrrelser relateret dertil
DK1799633T3 (da) Krystalformer af (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol-hydrochlorid til anvendelse som aktivt indholdsstof i farmaceutiske sammensætninger
ATE421518T1 (de) Dihydrochinazolinone als 5ht-modulatoren
NO20083204L (no) Kombinasjon av en H3-antagonist/inversagonist og en appetittdemper
NO343929B3 (no) 1-[2-(2,4-dimetylfenylsulfanyl-fenyl]-piperazin som en forbindelse med kombinert serotoninreopptak, 5-HT3- og 5HT1A-aktivitet for behandlingen av kognitiv smerte
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
IL216247A0 (en) Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
NO20070081L (no) Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer
EA200700489A1 (ru) Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
NO20075298L (no) Novel thiophene derivatives as sphingosine-1-phosphate-1 receptor agonists
DK3305776T3 (da) Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser
DK1668014T3 (da) Kondenserede heterocykliske forbindelser som serotoninreceptormodulatorer
NO20082793L (no) Nye tiofenderivater
NO20090175L (no) Stabile laquinimod sammensetninger
NO20061074L (no) Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet
EA201290255A1 (ru) Способы и композиции для лечения рака
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20080141L (no) Indanderivater som modulatorer av ionekanaler
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
NO20082285L (no) 3-aminosyklopentankarboksamider som modulatorer av kjemokinreseptorer